Table 2.
Group 0 | Group 1 | P | |
---|---|---|---|
CEPI-CT (sec) | |||
T0 | 133 ± 24 | 125 ± 30 | ns |
T1 | 153 ± 43 | 235 ± 67 | <0.01 |
T2 | 168 ± 46 | 258 ± 57 | <0.01 |
AA-MA (%) | |||
T0 | 10.5 ± 7.3 | 12.4 ± 6.2 | ns |
T1 | 10.6 ± 11.2 | 11.6 ± 10.0 | ns |
T2 | 12.0 ± 16.3 | 12.5 ± 10.7 | ns |
ADP-MA (%) | |||
T0 | 35.3 ± 17.3 | 39.5 ± 16.7 | ns |
T1 | 41.5 ± 14.3 | 38.5 ± 16.7 | ns |
T2 | 44.3 ± 21.6 | 42.9 ± 10.3 | ns |
VWF antigen (U/dL) | |||
T0 | 207 ± 54 | 219 ± 42 | ns |
T1 | 193 ± 52 | 168 ± 37 | <0.05 |
T2 | 195 ± 12 | 174 ± 44 | <0.05 |
ADAMT S-13 activity (%) | |||
T0 | 81 ± 26 | 75 ± 23 | ns |
T1 | 80 ± 22 | 96 ± 22 | <0.05 |
T2 | 85 ± 42 | 99 ± 37 | <0.05 |